Eisai’s Leqembi subcutaneous initiation treatment approved in China
Eisai Co., Ltd. says its Leqembi (Lecanemab) subcutaneous formulation for initiation treatment in early Alzheimer’s disease has been approved in China.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.